Effects of Barberry Capsules on Serum Zinc and Copper in Individuals with Metabolic Syndrome

Research Article

J Cardiovasc Disord. 2022; 8(1): 1050.

Effects of Barberry Capsules on Serum Zinc and Copper in Individuals with Metabolic Syndrome

Saberi-Karimian M1,2, Shaghi F1, Safarian H1, Saffar S1, Tavallaei S3, Navaei-Alipour N1, Shabani N4, Ferns GA5, Ghayour-Mobarhan M1*, Darroudi S1,2#, Kermany T6 and Zilae M1,5

1International UNESCO Center for Health Related Basic Sciences and Human Nutrition, Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

3Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4Department of Biostatistics & Epidemiology, School of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK

6Department of Anatomy, Birjand University of Medical Sciences, Birjand, Iran

#Co-Corresponding Author

*Corresponding author: Majid Ghayour-Mobarhan, International UNESCO Center for Health Related Basic Sciences and Human Nutrition, Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Received: February 12, 2022; Accepted:March 09, 2022; Published: March 16, 2022

Abstract

Aim: In current study, we aimed to investigate the effects of barberry on serum copper (Cu), zinc (Zn) and superoxide dismutase (SOD) levels in subjects with MetS, because of it are the anti-inflammatory and antioxidant properties.

Methods: 106 Subjects were randomly assigned to 2 study groups: 1) A barberry group receiving capsules containing 600 mg barberry daily for 6 weeks (n=53); 2) Control group contained subjects taking one placebo capsule daily (n=53). Atomic absorption was used to measure serum zinc and copper. SOD activity was measured using a pyrogallol indirect spectrophotometric assay.

Results: The results showed that there was no significant difference in changes in serum zinc between the barberry and placebo groups (p=0.620). There were significant differences in changes in serum copper between the 2 study groups (p<0.001). Moreover, there were significant differences in Zn/ Cu changes between the barberry and placebo groups (p=0.027). In addition, there were significant differences in changes in serum SOD1 between the study groups (p=0.077).

Conclusion: The results of the current study showed that barberry supplementation (600mg daily) for 6 weeks can increase serum copper and SOD1 levels and decrease the Zn/Cu ratio in patients with MetS.

Keywords: Metabolic syndrome; Barberry; Copper; Zinc; Superoxide dismutase

Abbreviations

Cu: Copper; CHD: Coronary Heart Disease; CVD: Cardiovascular Disease; GSH: Glutathione; GPX: Glutathione Peroxidase; MetS: Metabolic Syndrome; SOD Superoxide Dismutase; Zn: Zinc

Introduction

Metabolic syndrome (MetS) is a condition which characterized by a clustering of several cardiovascular risk factors, which include: central obesity, dyslipidemia, impaired glucose tolerance and hypertension [1]. Excessive intake of dietary calories and insufficient physical activity are two important reasons for the increasing prevalence of MetS in the world. In the United States about 70 million adults are obese and another 70 million are hypertensive. According to recent studies, obese individuals often have other features of MetS, such as dyslipidemia, hypertension and problems in insulin metabolic signaling [2]. Iran has a high prevalence rate of MetS, which affects 33% of the Iranian adult population [3].

MetS is associated with an increased level of oxidative stress. Oxidative stress has a pivotal role in pathophysiology of various diseases, including atherosclerosis and coronary heart disease (CHD) [4]. The activity of antioxidant enzymes such as superoxide dismutase has a crucial protective role in CHD and other chronic disease. The trace elements copper (Cu) and zinc (Zn) are important components of this enzyme. Recent studies have reported that zinc has an important role in the pathophysiology of MetS, by its participation in the regulation of cytokine expression and inflammation suppression. Zinc is also involved in the function of antioxidant enzymes and thereby it can reduce oxidative stress [5]. Intracellular zinc binds to several proteins and exerts an effect known as “protein redox zinc switch”. Oxidative stress can remove zinc from its position and then these ions can operate in signaling pathways, change the mitochondrial metabolism and effect on the cell redox situation [6]. Excessive levels of free copper ions can cause lipid oxidation, oxidative stress and the generation of reactive oxygen species and this finally causes some diseases [7].

Some foods derived from the Mediterranean region, such as Barberry, have beneficial effects on disease prevention and possibly their treatment [8].

Barberry has been reported to have anti-diabetic, anti-bacterial and anti-oxidant effects which have been used in medicines since ancient times. Barberry has also been reported to improve the serum cholesterol and triglycerides. Isoquinoline alkaloid, which is present in Barberry, and has been used for treatment of diseases including hyperlipidemia, CHD, diabetes and MetS may partially account for these effects [4].

Because of the importance of Zn and Cu to individuals with MetS, as well as the anti-inflammatory and antioxidant properties of barberry we aimed to investigate the effects of barberry on serum Zn and Cu in patients with MetS.

Materials and Methods

The current study was a substudy of our previous double-blind controlled trial on barberry in subjects with MetS which was approved by Mashhad University of Medical Sciences’ Ethics Committee [9]. It has been registered in the Iranian Registry of Clinical Trials (IRCT) with a registration number IRCT20110726007117N9. Inclusion and exclusion criteria were explained in detailed previously [9]. A total of 106 patients with MetS based on the International Diabetic Federation Criteria (IDF), who were referred to the Nutrition Clinic, were enrolled in this study.

Subjects were randomly assigned to 2 study groups: Group 1: Barberry group with subjects receiving Barberry capsules of 600 mg for 6 weeks (n=53); Group 2: Control group with subjects taking one Placebo capsule every day (n=53). The barberry and placebo capsules were prepared by Khoosheh Sorkhe Shargh Agro Industrial Company (Tehran, Iran). All subjects received nutritional advice based on American Heart Association guidelines about maintaining an isocaloric diet during the period of the study. A fasting blood sample was collected from all subjects at baseline and 6 weeks after the intervention.

Serum zinc and copper concentrations were determined using Atomic Absorption Spectrophotometer (Varian AA 240 FS model- America) [5,10]. Serum SOD activity was measured using pyrogallol indirect spectrophotometric assay [11].

Statistical analysis

All statistical analysis was undertaken using SPSS version 18 (SPSS Inc. Chicago, IL, USA). Data are presented as mean ± SD for quantitative data or number and percentage for qualitative data. T-test and Chi-square test were used for analysis at baseline and changes after intervention. Paired sample t-test was performed for analysis before and after intervention. All the analyses were two-sided and P values less than or equal to 0.05 were considered significant.

Results

The mean age of the study subjects was 38.96±9.04 and 40.89±9.61 years in the Barberry and Placebo groups, respectively (p>0.05). Female participants comprised 77.36% of the barberry group and 71.7% of the placebo group. There were no significant differences between gender distribution between the barberry and placebo groups, too (p>0.05) (Table 1).

Citation: Saberi-Karimian M, Shaghi F, Safarian H, Saffar S, Tavallaei S, Navaei-Alipour N, et al. Effects of Barberry Capsules on Serum Zinc and Copper in Individuals with Metabolic Syndrome. J Cardiovasc Disord. 2022; 8(1): 1050.